NASDAQ · Health care

ArriVent BioPharma, Inc. (AVBP)

It posted a net loss of $169.1M. At September 30, 2026 it held $113.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.

Watch AVBP in 60 seconds

Price

$13.49

-4.73% on the day · November 10, 2026

52-week range $11.36 to $35.83

Market cap

$665.2M

Key facts about ArriVent BioPharma, Inc.

Net worth: ArriVent BioPharma, Inc. has a market value (market cap) of $665.2M at the latest share price, and shareholders' equity of $393.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Cash flow: In fiscal 2025 operations used $160.6M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: ArriVent BioPharma, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What ArriVent BioPharma, Inc. does

ArriVent BioPharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AVBP.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$177.5M	-$166.3M	-$4.32	n/a
2024	n/a	-$94.3M	-$80.5M	-$2.56	n/a
2024	n/a	-$74.6M	-$69.3M	-$32.38	n/a

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around March 4, 2027.

Estimated from its filing rhythm: 52 weeks after its report of March 5, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Latest SEC filings

What ArriVent BioPharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 9, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue was $5M; diluted EPS -$0.81 versus -$0.83.
November 9, 2026
Quarterly results 8-K
November 5, 2026
Passive stake changed SCHEDULE 13G/A
October 26, 2026
Investor disclosure 8-K
October 19, 2026
Investor disclosure 8-K
October 13, 2026
Passive stake (5% or more) SCHEDULE 13G
October 13, 2026
Investor disclosure 8-K
October 8, 2026
Activist stake changed SCHEDULE 13D/A
October 6, 2026
Investor disclosure 8-K
August 12, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$1.05 versus -$0.90.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 2, 2026. Insider transactions on SEC

Insider trades

What the people running ArriVent BioPharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
October 30, 2026	LaChapelle RobinChief Operating Officer	Exercised options	16,265	$3.65	$59.4K	Form 4
October 30, 2026	LaChapelle RobinChief Operating Officer	Exercised options	410	$2.28	$935.4	Form 4
October 30, 2026	LaChapelle RobinChief Operating Officer	Exercised options	4,550	$2.28	$10.4K	Form 4
October 30, 2026	LaChapelle RobinChief Operating Officer	Exercised options	1,820	$2.28	$4.2K	Form 4
October 30, 2026	LaChapelle RobinChief Operating Officer	Exercised options	17,648	$6.24	$110.1K	Form 4
December 10, 2025	Hillhouse Investment Management, Ltd.10% owner	Soldindirect	555,555	$23.37	$13M	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns AVBP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
HHLR Advisors, Ltd.13G, passive with 1 related filers	13.4%	4,484,672	November 14, 2024
Infinitum Asset Management, LLC13G, passive with 2 related filers	9.9%	4,123,923	February 17, 2026
Suvretta Capital Management, LLC13G, passive with 2 related filers	9.9%	3,412,788	August 13, 2025
Hillhouse Investment Management, Ltd.13G, passive	9.5%	3,929,117	February 17, 2026
Fmr LLC13G, passive with 1 related filers	6.8%	3,016,132	May 6, 2026
Orbimed Advisors LLC13D, may seek influence with 3 related filers	5.8%	2,875,962	October 8, 2026
HBM Healthcare Investments (Cayman) Ltd.13G, passive	5.4%	2,195,014	October 15, 2025
Vivo Opportunity, LLC13G, passive with 5 related filers	5%	2,472,701	October 13, 2026

Latest filings below 5%: Sofinnova Venture Partners XI, L.P. ("SVP XI") 4.1% (March 5, 2026); The Vanguard Group 4.52% (January 30, 2026); Octagon Capital Advisors LP 4.9% (November 14, 2025); Novo Holdings A/S 4.9% (August 14, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 4,105,546 shares in total, about $55.4M at the last price.

Holder	Shares	As of
Hillhouse Investment Management, Ltd.10% owner	3,929,1173,929,117 held indirectly	December 10, 2025
LaChapelle RobinChief Operating Officer	176,429	October 30, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about AVBP

What does ArriVent BioPharma, Inc. do?

ArriVent BioPharma, Inc. is a company in the Health care sector, listed on NASDAQ as AVBP. Its shares trade on NASDAQ under the ticker AVBP.

What is ArriVent BioPharma, Inc.'s net worth?

ArriVent BioPharma, Inc. has a market value (market cap) of $665.2M at the latest share price, and shareholders' equity of $393.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is ArriVent BioPharma, Inc. profitable?

No. Over the twelve months to September 30, 2026 it reported a net loss of $169.1M.

When did ArriVent BioPharma, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.

When is ArriVent BioPharma, Inc.'s next earnings report?

ArriVent BioPharma, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

SLN

Silence Therapeutics plc

VSTM

Verastem, Inc.

CBIO

Crescent Biopharma, Inc.

ZVRA

Zevra Therapeutics, Inc.

SGMT

Sagimet Biosciences Inc.

EVO

Evotec SE

Compare AVBP with

Compare AVBP with any company

Follow AVBP

Get an email when ArriVent BioPharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values ArriVent BioPharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.